{"id":"spiriva-handihaler","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dry mouth"},{"rate":"1-3","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"1-2","effect":"Urinary retention"},{"rate":"1-2","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1900528","moleculeType":"Small molecule","molecularWeight":"392.52"},"_dailymed":{"setId":"820839ef-e53d-47e8-a3b9-d911ff92e6a9","title":"SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE) CAPSULE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium is a selective M3 muscarinic receptor antagonist that prevents acetylcholine-induced bronchoconstriction. By blocking these receptors on airway smooth muscle, it produces sustained bronchodilation lasting 24 hours or longer. This reduces airway obstruction and improves lung function in chronic obstructive pulmonary disease (COPD) and asthma.","oneSentence":"Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:51.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment"}]},"trialDetails":[{"nctId":"NCT02683668","phase":"PHASE3","title":"Airway Effects of Tiotropium in Patients With COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-02-01","conditions":"COPD, LUNG DISEASES, OBSTRUCTIVE","enrollment":44},{"nctId":"NCT05506865","phase":"PHASE4","title":"Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2012-09","conditions":"COPD","enrollment":73},{"nctId":"NCT05362487","phase":"","title":"Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2022-08-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9},{"nctId":"NCT02175342","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":202},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT02627625","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products","status":"COMPLETED","sponsor":"Solventum US LLC","startDate":"2015-11","conditions":"Healthy","enrollment":31},{"nctId":"NCT06487416","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-06-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":186},{"nctId":"NCT04672941","phase":"","title":"Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1396},{"nctId":"NCT06326671","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-02-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":39},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT00239447","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT03964207","phase":"PHASE4","title":"A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":72},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05838703","phase":"PHASE2","title":"Tiotropium Handihaler vs. Tiotropium Respimat in COPD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2023-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT05246046","phase":"PHASE1","title":"Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2022-02-16","conditions":"Healthy Volunteers","enrollment":88},{"nctId":"NCT00662792","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":147},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT04850144","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-04-26","conditions":"Healthy Volunteers","enrollment":43},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT02586649","phase":"PHASE2","title":"24hr Effects of Tiotropium Bromide in Tetraplegia","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2014-07","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT02541006","phase":"PHASE4","title":"Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-11","conditions":"COPD","enrollment":58},{"nctId":"NCT02988869","phase":"PHASE4","title":"Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-08","conditions":"COPD","enrollment":84},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT04147572","phase":"NA","title":"Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-11-01","conditions":"Healthy Volunteer, COPD","enrollment":200},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT02039050","phase":"PHASE4","title":"Evaluation of Long-Acting Muscarinic Antagonists in COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":15},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT02172430","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":161},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02275481","phase":"PHASE4","title":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":66},{"nctId":"NCT03400241","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2018-02-19","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT01426009","phase":"PHASE2","title":"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT02276222","phase":"PHASE3","title":"A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2014-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1087},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT01395888","phase":"PHASE3","title":"A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":260},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT01627327","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT00555022","phase":"PHASE1","title":"Effect of GSK1160724 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":21},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT02125734","phase":"PHASE4","title":"Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":88},{"nctId":"NCT02331940","phase":"NA","title":"Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients","status":"COMPLETED","sponsor":"University of Crete","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT01970878","phase":"PHASE3","title":"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":892},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00361959","phase":"PHASE4","title":"SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1270},{"nctId":"NCT01462929","phase":"PHASE3","title":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":414},{"nctId":"NCT00868231","phase":"PHASE2","title":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01455129","phase":"PHASE4","title":"Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01587079","phase":"PHASE2","title":"Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT00546234","phase":"PHASE4","title":"Tiotropium for Smoking Asthmatics Study","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2007-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT01959516","phase":"PHASE4","title":"Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02","conditions":"COPD","enrollment":124},{"nctId":"NCT02473237","phase":"PHASE4","title":"Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2013-04","conditions":"COPD","enrollment":40},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT01437748","phase":"PHASE4","title":"Closing Volume Interpretation and Bronchodilators Effect","status":"COMPLETED","sponsor":"University of Milan","startDate":"2011-08","conditions":"Healthy, COPD","enrollment":40},{"nctId":"NCT02254174","phase":"PHASE1","title":"Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT01694771","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1134},{"nctId":"NCT01785433","phase":"PHASE1, PHASE2","title":"To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"COPD","enrollment":36},{"nctId":"NCT01040689","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":108},{"nctId":"NCT01040728","phase":"PHASE3","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT02172300","phase":"PHASE3","title":"Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":198},{"nctId":"NCT02172521","phase":"","title":"Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1536},{"nctId":"NCT02172326","phase":"PHASE3","title":"Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":29},{"nctId":"NCT01126437","phase":"PHASE3","title":"Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17183},{"nctId":"NCT01483625","phase":"PHASE4","title":"Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":140},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT01644734","phase":"PHASE4","title":"Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1328},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT00523991","phase":"PHASE4","title":"Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":457},{"nctId":"NCT01222533","phase":"PHASE2","title":"Tiotropium Respimat Pharmacokinetic Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":154},{"nctId":"NCT01613326","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":657},{"nctId":"NCT00613574","phase":"","title":"RUSSE / Russian Spiriva® Safety & Efficacy Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"","conditions":"COPD","enrollment":407},{"nctId":"NCT00624377","phase":"","title":"Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2031},{"nctId":"NCT01285492","phase":"PHASE3","title":"Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":160},{"nctId":"NCT00525512","phase":"PHASE4","title":"Tiotropium In Exercise","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-08","conditions":"Pulmonary Disease, Chronic Obstructive, Exercise","enrollment":519},{"nctId":"NCT00563381","phase":"PHASE4","title":"Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":7376}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20081113","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20160324","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20110728","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20241230","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20061208","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20060920","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20180201","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20150423","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20160623","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20040823","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20040130","type":"ORIG","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20160429","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20111104","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20151210","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20080620","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20090303","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20061208","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20150422","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20151026","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"},{"date":"20091217","type":"SUPPL","sponsor":"BOEHRINGER INGELHEIM","applicationNumber":"NDA021395"}],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LAMA"],"phase":"marketed","status":"active","brandName":"Spiriva HandiHaler","genericName":"Spiriva HandiHaler","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}